Abstract
It was postulated that N6-allyl bicyclic derivatives 1 bind with N-8 at the proton donor site of the σ1 receptor and that a substituent in 2-position of the bicyclic framework 1 results in unfavorable steric interactions with the σ1 receptor protein. In order to support this hypothesis both enantiomers of 6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[ 3.2.2]non-2-ene (2/ent-2) and 6-benzyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane 3/ent-3 were synthesized stereoselectively. The (S,S)-configured enantiomers 2 and 3 are the eutomers with eudismic ratios of 31 and 4.8, respectively. Therefore, these enantiomers are used in the σ1 pharmacophore model. The N6-allyl derivative 2 with a double bond in the three carbon bridge adopts the orientation 2c with N-8 interacting with the σ1 receptor proton donor site (Fig. 2) resulting in slightly reduced steric interactions of the small double bond in 2/3-position. The almost C2-symmetric benzyl derivative 3 can adopt both orientations 2c and 2d at the σ1 receptor (N-8 or N-6 interacts with the σ 1 receptor proton donor site) resulting in subnanomolar σ1 receptor affinity (Ki = 0.91 nM).
Keywords: ??1 receptor ligands: 6,8-diazabicyclo[3.2.2]nonanes, 6,8-diazabicyclo[3.2.2]nonenes, pharmacophore model
Central Nervous System Agents in Medicinal Chemistry
Title: Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Volume: 9 Issue: 3
Author(s): Ralph Holl, Christian Geiger, Masakazu Nambo, Kenichiro Itami, Dirk Schepmann and Bernhard Wunsch
Affiliation:
Keywords: ??1 receptor ligands: 6,8-diazabicyclo[3.2.2]nonanes, 6,8-diazabicyclo[3.2.2]nonenes, pharmacophore model
Abstract: It was postulated that N6-allyl bicyclic derivatives 1 bind with N-8 at the proton donor site of the σ1 receptor and that a substituent in 2-position of the bicyclic framework 1 results in unfavorable steric interactions with the σ1 receptor protein. In order to support this hypothesis both enantiomers of 6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[ 3.2.2]non-2-ene (2/ent-2) and 6-benzyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane 3/ent-3 were synthesized stereoselectively. The (S,S)-configured enantiomers 2 and 3 are the eutomers with eudismic ratios of 31 and 4.8, respectively. Therefore, these enantiomers are used in the σ1 pharmacophore model. The N6-allyl derivative 2 with a double bond in the three carbon bridge adopts the orientation 2c with N-8 interacting with the σ1 receptor proton donor site (Fig. 2) resulting in slightly reduced steric interactions of the small double bond in 2/3-position. The almost C2-symmetric benzyl derivative 3 can adopt both orientations 2c and 2d at the σ1 receptor (N-8 or N-6 interacts with the σ 1 receptor proton donor site) resulting in subnanomolar σ1 receptor affinity (Ki = 0.91 nM).
Export Options
About this article
Cite this article as:
Holl Ralph, Geiger Christian, Nambo Masakazu, Itami Kenichiro, Schepmann Dirk and Wunsch Bernhard, Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030220
DOI https://dx.doi.org/10.2174/1871524910909030220 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Current Drug Metabolism Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase.
CNS & Neurological Disorders - Drug Targets Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Toward the Identification of Novel Carbonic Anhydrase XIV Inhibitors using 3D-QSAR Pharmacophore Model, Virtual Screening and Molecular Docking Study
Letters in Drug Design & Discovery Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Glutamate Receptors and Related Processes as Drug Targets (Guest Editor: Michel Baudry)]
Current Drug Targets Relevance of CYP2C9 Function in Valproate Therapy
Current Neuropharmacology Valproic acid, A Potential Inducer of Osteogenesis in Mouse Mesenchymal Stem Cells
Current Molecular Pharmacology Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design